PDCD1 and non-small cell lung carcinoma: One study found that in non-small cell lung cancer (NSCLC) patients treated with anti-PD-1 therapy, the expression of thyroid transcription factor-1 (TTF-1) in tumor tissue has been significantly correlated with both the incidence of ICI-induced thyroiditis and the clinical efficacy of ICI therapy (47).